High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma

The optimal salvage therapy in relapsed/refractory Hodgkin lymphoma (R/R HL) has not been defined so far. The goal of this multicenter retrospective study was to evaluate efficacy and safety of BGD (bendamustine, gemcitabine, dexamethasone) as a second or subsequent line of therapy in classical R/R...

Descripción completa

Detalles Bibliográficos
Autores principales: Swoboda, Ryszard, Giebel, Sebastian, Knopińska-Posłuszny, Wanda, Chmielowska, Ewa, Drozd-Sokołowska, Joanna, Paszkiewicz-Kozik, Ewa, Kulikowski, Waldemar, Taszner, Michał, Mendrek, Włodzimierz, Najda, Jacek, Czerw, Tomasz, Olszewska-Szopa, Magdalena, Czyż, Anna, Giza, Agnieszka, Spychałowicz, Wojciech, Subocz, Edyta, Szwedyk, Paweł, Krzywon, Aleksandra, Wilk, Agata, Zaucha, Jan Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195914/
https://www.ncbi.nlm.nih.gov/pubmed/33625572
http://dx.doi.org/10.1007/s00277-021-04448-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195914/
https://www.ncbi.nlm.nih.gov/pubmed/33625572
http://dx.doi.org/10.1007/s00277-021-04448-5

Ejemplares similares